Updated on 2024/08/02

写真a

 
OHARA Yuki
 
Organization
Graduate School of Medicine Center for Research of Laboratory Animals and Medical Research Engineering Division Designated assistant professor
Title
Designated assistant professor
Other name(s)
Ohara Yuuki
External link

Degree 1

  1. Doctor (Medicine) ( 2018.3   Nagoya University ) 

Research Interests 1

  1. 発がん 酸化ストレス 鉄代謝 メタボロミクス トランスクリプトミクス がん微小環境

Research Areas 1

  1. Life Science / Experimental pathology

Current Research Project and SDGs 1

  1. がんの分子・代謝プロファイリング

Research History 5

  1. Nagoya University   Graduate School of Medicine Center for Research of Laboratory Animals and Medical Research Engineering Division   Designated assistant professor

    2024.6

  2. National Institutes of Health   National Cancer Institute, Laboratory of Human Carcinogenesis   Special volunteer (客員研究員)

    2024.5

      More details

    Country:United States

  3. National Institutes of Health   National Cancer Institute, Laboratory of Human Carcinogenesis   Postdoctoral Fellow

    2019.5 - 2024.4

      More details

  4. National Cancer Center

    2018.4 - 2019.5

      More details

  5. 愛知厚生連海南病院   初期臨床研修医

    2012.4 - 2014.3

      More details

Education 2

  1. Nagoya University

    2014.4 - 2018.3

  2. Hirosaki University

    2006.4 - 2012.3

Professional Memberships 4

  1. American Association for Cancer Research

      More details

  2. 日本病理学会

      More details

  3. 日本癌学会

      More details

  4. 日本酸化ストレス学会

      More details

Committee Memberships 2

  1. Free Radical Biology and Medicine   Editorial board member  

    2021   

      More details

  2. Pathology International   Editorial board member  

    2021 - 2023   

      More details

Awards 7

  1. Fellows Award for Research Excellence (FARE) 2025

    2024.7   National Institutes of Health   ADRA2A promotes the classical/progenitor subtype and reduces disease aggressiveness of pancreatic cancer

     More details

  2. 日本病理学会学術奨励賞

    2024.3   日本病理学会   オミクス解析を用いたがんの分子サブタイプと代謝の誘導メカニズムの解明

     More details

  3. 2024 UJA論文賞 奨励賞

    2024.3   海外日本人研究者ネットワーク  

     More details

  4. SFRR Japan Young Investigator Award

    2017.12   Society for Free Radical Research Asia   Phlebotomy as a preventive measure for crocidolite-induced mesothelioma in male rats

     More details

  5. 日本病理学会100周年記念病理学研究新人賞

    2017.4   日本病理学会   悪性中皮腫の新規治療法・予防法の開発

     More details

  6. ベストプレゼンテーション賞(第9回NAGOYAグローバルリトリート)

    2017.2   名古屋大学  

     More details

  7. Society for Free Radical Research Asia travel award

    2016.11   Society for Free Radical Research Asia   Preclinical use of CTGF-specific monoclonal antibody for the treatment of malignant mesothelioma

     More details

▼display all

 

Papers 20

  1. ELAPOR1 induces the classical/progenitor subtype and contributes to reduced disease aggressiveness through metabolic reprogramming in pancreatic cancer International journal

    Yuuki Ohara, Huaitian Liu, Amanda J. Craig, Shouhui Yang, Paloma Moreno, Tiffany H. Dorsey, Helen Cawley, Azadeh Azizian, Jochen Gaedcke, Michael Ghadimi, Nader Hanna, Stefan Ambs, S. Perwez Hussain

    International Journal of Cancer     2024.4

     More details

    Publishing type:Research paper (scientific journal)   Publisher:Wiley  

    Abstract

    Pancreatic ductal adenocarcinoma (PDAC) is a heterogeneous disease with distinct molecular subtypes described as classical/progenitor and basal‐like/squamous PDAC. We hypothesized that integrative transcriptome and metabolome approaches can identify candidate genes whose inactivation contributes to the development of the aggressive basal‐like/squamous subtype. Using our integrated approach, we identified endosome–lysosome associated apoptosis and autophagy regulator 1 (ELAPOR1/KIAA1324) as a candidate tumor suppressor in both our NCI‐UMD‐German cohort and additional validation cohorts. Diminished ELAPOR1 expression was linked to high histological grade, advanced disease stage, the basal‐like/squamous subtype, and reduced patient survival in PDAC. In vitro experiments demonstrated that ELAPOR1 transgene expression not only inhibited the migration and invasion of PDAC cells but also induced gene expression characteristics associated with the classical/progenitor subtype. Metabolome analysis of patient tumors and PDAC cells revealed a metabolic program associated with both upregulated ELAPOR1 and the classical/progenitor subtype, encompassing upregulated lipogenesis and downregulated amino acid metabolism. 1‐Methylnicotinamide, a known oncometabolite derived from S‐adenosylmethionine, was inversely associated with ELAPOR1 expression and promoted migration and invasion of PDAC cells in vitro. Taken together, our data suggest that enhanced ELAPOR1 expression promotes transcriptome and metabolome characteristics that are indicative of the classical/progenitor subtype, whereas its reduction associates with basal‐like/squamous tumors with increased disease aggressiveness in PDAC patients. These findings position ELAPOR1 as a promising candidate for diagnostic and therapeutic targeting in PDAC.

    DOI: 10.1002/ijc.34960

    researchmap

  2. LMO3 is a suppressor of the basal-like/squamous subtype and reduces disease aggressiveness of pancreatic cancer through glycerol 3-phosphate metabolism International journal

    Yuuki Ohara, Amanda J Craig, Huaitian Liu, Shouhui Yang, Paloma Moreno, Tiffany H Dorsey, Helen Cawley, Azadeh Azizian, Jochen Gaedcke, Michael Ghadimi, Nader Hanna, Stefan Ambs, S Perwez Hussain

    Carcinogenesis     2024.2

     More details

    Publishing type:Research paper (scientific journal)  

    DOI: 10.1093/carcin/bgae011

    researchmap

  3. SERPINB3-MYC axis induces the basal-like/squamous subtype and enhances disease progression in pancreatic cancer International journal

    Yuuki Ohara, Wei Tang, Huaitian Liu, Shouhui Yang, Tiffany H. Dorsey, Helen Cawley, Paloma Moreno, Raj Chari, Mary R. Guest, Azadeh Azizian, Jochen Gaedcke, Michael Ghadimi, Nader Hanna, Stefan Ambs, S. Perwez Hussain

    Cell Reports     2023.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.celrep.2023.113434

    researchmap

  4. Diabetes-associated breast cancer is molecularly distinct and shows a DNA damage repair deficiency International journal

    Gatikrushna Panigrahi, Julián Candia, Tiffany H. Dorsey, Wei Tang, Yuuki Ohara, Jung S. Byun, Tsion Zewdu Minas, Amy Zhang, Anuoluwapo Ajao, Ashley Cellini, Harris G. Yfantis, Amy L. Flis, Dean Mann, Olga Ioffe, Xin W. Wang, Huaitian Liu, Christopher A. Loffredo, Anna Maria Napoles, Stefan Ambs

    JCI Insight     2023.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1172/jci.insight.170105

    researchmap

  5. Dysregulation of HNF1B/Clusterin axis enhances disease progression in a highly aggressive subset of pancreatic cancer patients International journal

    Shouhui Yang, Wei Tang, Azadeh Azizian, Jochen Gaedcke, Philipp Ströbel, Limin Wang, Helen Cawley, Yuuki Ohara, Paloma Valenzuela, Lin Zhang, Trisha Lal, Sanju Sinha, Eythan Rupin, Nader Hanna, B Michael Ghadimi, S Perwez Hussain

    Carcinogenesis     2022.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    <jats:title>Abstract</jats:title>
    <jats:p>Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy and is largely refractory to available treatments. Identifying key pathways associated with disease aggressiveness and therapeutic resistance may characterize candidate targets to improve patient outcomes. We used a strategy of examining the tumors from a subset of PDAC patient cohorts with the worst survival to understand the underlying mechanisms of aggressive disease progression and to identify candidate molecular targets with potential therapeutic significance. Non-negative matrix factorization (NMF) clustering, using gene expression profile, revealed three patient subsets. A 142-gene signature specific to the subset with the worst patient survival, predicted prognosis and stratified patients with significantly different survival in the test and validation cohorts. Gene-network and pathway analysis of the 142-gene signature revealed dysregulation of Clusterin (CLU) in the most aggressive patient subset in our patient cohort. Hepatocyte nuclear factor 1 b (HNF1B) positively regulated CLU, and a lower expression of HNF1B and CLU was associated with poor patient survival. Mechanistic and functional analyses revealed that CLU inhibits proliferation, 3D spheroid growth, invasiveness and epithelial-to-mesenchymal transition (EMT) in pancreatic cancer cell lines. Mechanistically, CLU enhanced proteasomal degradation of EMT-regulator, ZEB1. In addition, orthotopic transplant of CLU-expressing pancreatic cancer cells reduced tumor growth in mice. Furthermore, CLU enhanced sensitivity of pancreatic cancer cells representing aggressive patient subset, to the chemotherapeutic drug gemcitabine. Taken together, HNF1B/CLU axis negatively regulates pancreatic cancer progression and may potentially be useful in designing novel strategies to attenuate disease progression in PDAC patients.</jats:p>

    DOI: 10.1093/carcin/bgac092

    researchmap

  6. The interactive role of inflammatory mediators and metabolic reprogramming in pancreatic cancer International journal

    Yuuki Ohara, Paloma Valenzuela, S. Perwez Hussain

    Trends in Cancer     2022.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Elsevier {BV}  

    DOI: 10.1016/j.trecan.2022.03.004

    researchmap

  7. Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments International journal

    Shogo Kumagai, Shohei Koyama, Kota Itahashi, Tokiyoshi Tanegashima, Yi-tzu Lin, Yosuke Togashi, Takahiro Kamada, Takuma Irie, Genki Okumura, Hidetoshi Kono, Daisuke Ito, Rika Fujii, Sho Watanabe, Atsuo Sai, Shota Fukuoka, Eri Sugiyama, Go Watanabe, Takuya Owari, Hitomi Nishinakamura, Daisuke Sugiyama, Yuka Maeda, Akihito Kawazoe, Hiroki Yukami, Keigo Chida, Yuuki Ohara, Tatsuya Yoshida, Yuki Shinno, Yuki Takeyasu, Masayuki Shirasawa, Kenta Nakama, Keiju Aokage, Jun Suzuki, Genichiro Ishii, Takeshi Kuwata, Naoya Sakamoto, Masahito Kawazu, Toshihide Ueno, Taisuke Mori, Naoya Yamazaki, Masahiro Tsuboi, Yasushi Yatabe, Takahiro Kinoshita, Toshihiko Doi, Kohei Shitara, Hiroyuki Mano, Hiroyoshi Nishikawa

    Cancer Cell   Vol. 40 ( 2 ) page: 201 - 218.e9   2022.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Elsevier {BV}  

    DOI: 10.1016/j.ccell.2022.01.001

    researchmap

  8. Drug-exposed cancer-associated fibroblasts facilitate gastric cancer cell progression following chemotherapy International journal

    Takahiro Ishii, Ayako Suzuki, Takeshi Kuwata, Shoshi Hisamitsu, Hiroko Hashimoto, Yuuki Ohara, Kazuyoshi Yanagihara, Shuichi Mitsunaga, Takayuki Yoshino, Takahiro Kinoshita, Atsushi Ochiai, Kohei Shitara, Genichiro Ishii

    Gastric Cancer   Vol. 24 ( 4 ) page: 810 - 822   2021.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Springer Science and Business Media {LLC}  

    DOI: 10.1007/s10120-021-01174-9

    researchmap

  9. The critical role of CD4+ T cells in PD-1 blockade against MHC-II–expressing tumors such as classic Hodgkin lymphoma International journal

    Joji Nagasaki, Yosuke Togashi, Takeaki Sugawara, Makiko Itami, Nobuhiko Yamauchi, Junichiro Yuda, Masato Sugano, Yuuki Ohara, Yosuke Minami, Hirohisa Nakamae, Masayuki Hino, Masahiro Takeuchi, Hiroyoshi Nishikawa

    Blood Advances   Vol. 4 ( 17 ) page: 4069 - 4082   2020.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:American Society of Hematology  

    <jats:title>Abstract</jats:title>
    <jats:p>Classic Hodgkin lymphoma (cHL) responds markedly to PD-1 blockade therapy, and the clinical responses are reportedly dependent on expression of major histocompatibility complex class II (MHC-II). This dependence is different from other solid tumors, in which the MHC class I (MHC-I)/CD8+ T-cell axis plays a critical role. In this study, we investigated the role of the MHC-II/CD4+ T-cell axis in the antitumor effect of PD-1 blockade on cHL. In cHL, MHC-I expression was frequently lost, but MHC-II expression was maintained. CD4+ T cells highly infiltrated the tumor microenvironment of MHC-II–expressing cHL, regardless of MHC-I expression status. Consequently, CD4+ T-cell, but not CD8+ T-cell, infiltration was a good prognostic factor in cHL, and PD-1 blockade showed antitumor efficacy against MHC-II–expressing cHL associated with CD4+ T-cell infiltration. Murine lymphoma and solid tumor models revealed the critical role of antitumor effects mediated by CD4+ T cells: an anti-PD-1 monoclonal antibody exerted antitumor effects on MHC-I−MHC-II+ tumors but not on MHC-I−MHC-II− tumors, in a cytotoxic CD4+ T-cell–dependent manner. Furthermore, LAG-3, which reportedly binds to MHC-II, was highly expressed by tumor-infiltrating CD4+ T cells in MHC-II–expressing tumors. Therefore, the combination of LAG-3 blockade with PD-1 blockade showed a far stronger antitumor immunity compared with either treatment alone. We propose that PD-1 blockade therapies have antitumor effects on MHC-II–expressing tumors such as cHL that are mediated by cytotoxic CD4+ T cells and that LAG-3 could be a candidate for combination therapy with PD-1 blockade.</jats:p>

    DOI: 10.1182/bloodadvances.2020002098

    researchmap

  10. Connective tissue growth factor produced by cancer‑associated fibroblasts correlates with poor prognosis in epithelioid malignant pleural mesothelioma International journal

    Yuuki Ohara, Atsushi Enomoto, Yuta Tsuyuki, Kotaro Sato, Tadashi Iida, Hiroki Kobayashi, Yasuyuki Mizutani, Yuki Miyai, Akitoshi Hara, Shinji Mii, Jun Suzuki, Kyoko Yamashita, Fumiya Ito, Yashiro Motooka, Nobuaki Misawa, Takayuki Fukui, Koji Kawaguchi, Kohei Yokoi, Shinya Toyokuni

    Oncology Reports   Vol. 44 ( 3 ) page: 838 - 848   2020.7

     More details

    Publishing type:Research paper (scientific journal)   Publisher:Spandidos Publications  

    DOI: 10.3892/or.2020.7669

    researchmap

  11. Clinicopathological characteristics associated with necrosis in pulmonary metastases from colorectal cancer International journal

    Jun Suzuki, Motohiro Kojima, Keiju Aokage, Takashi Sakai, Hiroshi Nakamura, Yuuki Ohara, Kenta Tane, Tomohiro Miyoshi, Masato Sugano, Satoshi Fujii, Takeshi Kuwata, Atsushi Ochiai, Masaaki Ito, Kenji Suzuki, Masahiro Tsuboi, Genichiro Ishii

    Virchows Archiv   Vol. 474 ( 5 ) page: 569 - 575   2019.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Springer Science and Business Media LLC  

    DOI: 10.1007/s00428-019-02535-7

    researchmap

    Other Link: http://link.springer.com/content/pdf/10.1007/s00428-019-02535-7.pdf

  12. Non-thermal plasma specifically kills oral squamous cell carcinoma cells in a catalytic Fe(II)-dependent manner International journal

    Kotaro Sato, Lei Shi, Fumiya Ito, Yuuki Ohara, Yashiro Motooka, Hiromasa Tanaka, Masaaki Mizuno, Masaru Hori, Tasuku Hirayama, Hideharu Hibi, Shinya Toyokuni

    Journal of Clinical Biochemistry and Nutrition   Vol. 65 ( 1 ) page: 8 - 15   2019

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:The Society for Free Radical Research Japan  

    DOI: 10.3164/jcbn.18-91

    researchmap

  13. Acute fulminant invasive pulmonary aspergillosis in an immunocompetent host: An autopsy case report International journal

    Yuuki Ohara, Takahiko Ito, Makoto Ito, Kyoko Yamashita, Shinya Toyokuni

    Medical Mycology Case Reports   Vol. 20   page: 39 - 42   2018.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Elsevier BV  

    DOI: 10.1016/j.mmcr.2018.02.002

    researchmap

  14. Connective tissue growth factor-specific monoclonal antibody inhibits growth of malignant mesothelioma in an orthotopic mouse model International journal

    Yuuki Ohara, Shan Hwu Chew, Nobuaki Misawa, Shenqi Wang, Daiki Somiya, Kae Nakamura, Hiroaki Kajiyama, Fumitaka Kikkawa, Yuta Tsuyuki, Li Jiang, Kyoko Yamashita, Yoshitaka Sekido, Kenneth E. Lipson, Shinya Toyokuni

    Oncotarget   Vol. 9 ( 26 ) page: 18494 - 18509   2018.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Impact Journals, LLC  

    DOI: 10.18632/oncotarget.24892

    researchmap

  15. An autopsy case report: Differences in radiological images correlate with histology in Erdheim–Chester disease International journal

    Yuuki Ohara, Seiichi Kato, Daisuke Yamashita, Akira Satou, Yoshie Shimoyama, Chie Hamaie, Motoki Sato, Nobutaro Ban, Koji Yamamoto, Takehiro Yamada, Hisashi Kawai, Koichi Ohshima, Shigeo Nakamura, Shinya Toyokuni

    Pathology International   Vol. 68 ( 6 ) page: 374 - 381   2018.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Wiley  

    p16 activation caused by oncogenic mutations may represent oncogene‐induced senescence (OIS), a protective mechanism against oncogenic events. However, OIS can contribute to tumor development via tissue remodeling in some tumors. Erdheim–Chester disease (ECD), a rare non‐Langerhans cell histiocytosis, is one such tumor. Its clinical and histological features vary, making it difficult to diagnose. Herein, we describe an autopsy of an ECD patient. The patient underwent radiological examinations, including <sup>18</sup>F‐fluorodeoxyglucose (FDG)‐positron emission tomography/computed tomography (PET/CT), bone scintigraphy and CT. A biopsy from the lesion with the highest FDG accumulation confirmed the presence of foamy macrophages, a diagnostic clue for ECD. Based on this finding and the clinical features, ECD was diagnosed. However, the patient died from heart dysfunction. After the autopsy, each radiologically different site showed various histological findings regarding the morphology of macrophages, fibrosis, inflammation, and p16 expression. OIS‐induced histological progression can cause certain changes observed in radiological images. In addition, in order to evaluate the increase in glucose metabolism, which can affect FDG accumulation, the expression of glucose transporter 1 and hexokinase II was also analyzed. Summarizing the radio‐histological correlation can help further both the understanding and diagnosis of ECD.

    DOI: 10.1111/pin.12663

    researchmap

  16. Phlebotomy as a preventive measure for crocidolite‐induced mesothelioma in male rats International journal

    Yuuki Ohara, Shan‐Hwu Chew, Takahiro Shibata, Yasumasa Okazaki, Kyoko Yamashita, Shinya Toyokuni

    Cancer Science   Vol. 109 ( 2 ) page: 330 - 339   2018.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Wiley  

    Malignant mesothelioma (MM) is a rare but socially important neoplasm due to its association with asbestos exposure. Malignant mesothelioma is difficult to diagnose at an early stage, yet there are no particularly effective treatments available at the advanced stage, thus necessitating efficient strategies to prevent MM in individuals already exposed to asbestos. We previously showed that persistent oxidative damage caused by foreign body reaction and affinity of asbestos both to hemoglobin and histones is one of the major pathogeneses. Accordingly, as an effective strategy to prevent asbestos‐induced MM, we undertook the use of an iron chelator, deferasirox, which decreased the epithelial–mesenchymal transition in a crocidolite‐induced rat MM model. However, this agent may show adverse effects. Here, we studied the effects of iron removal by phlebotomy as a realistic measure on the same rat model. We injected a total of 5 mg crocidolite i.p. to F1 hybrid rats between the Fischer‐344 and Brown‐Norway strains at the age of 6 weeks. We repeated weekly or biweekly phlebotomy of 6‐8 mL/kg/time from 10 to 60 weeks of age. The animals were observed until 120 weeks. In male rats, phlebotomy significantly decreased the weight and nuclear grade of MM, and modestly reduced the associated ascites and the fraction of more malignant sarcomatoid subtype. Weekly phlebotomy prolonged long‐term survival. Our results indicate that appropriate phlebotomy may be a practical preventive measure to attenuate the initiation and promotion capacity of asbestos towards MM by reducing iron in individuals exposed to asbestos.

    DOI: 10.1111/cas.13460

    researchmap

  17. Osteogenic differentiation in dedifferentiated liposarcoma: a study of 36 cases in comparison to the cases without ossification International journal

    Kyoko Yamashita, Kenichi Kohashi, Yuichi Yamada, Takeaki Ishii, Yoshihiro Nishida, Hiroshi Urakawa, Ichiro Ito, Mitsuru Takahashi, Takeshi Inoue, Masafumi Ito, Yuuki Ohara, Yoshinao Oda, Shinya Toyokuni

    Histopathology   Vol. 72 ( 5 ) page: 729 - 738   2017.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Wiley  

    Aims

    Ossification is found occasionally in dedifferentiated liposarcoma (DDLPS). The aims of this study were to elucidate whether the formed bone tissue is usually produced by tumour cells or by reactive non‐neoplastic cells, and to reveal the clinicopathological characteristics of DDLPS with ossification.

    Methods and results

    We examined 36 cases of ossified DDLPS by comparing them to 31 cases of non‐ossified DDLPS. MDM2 amplification was confirmed in osteocytes and/or osteoblastic cells in all but one ossified DDLPS cases (27 of 28) using fluorescence in‐situ hybridisation, although the morphological impression of ossification appeared to be mainly metaplastic (27 of 36) or high‐grade osteosarcoma‐like (six of 36). The bone tissue was often formed predominantly at the periphery of the DDLPS area near the well‐differentiated liposarcoma component (18 of 36), and an organised structure such as bone marrow‐like differentiation was not uncommon (12 of 36). According to a modified French Fédération Nationale des Centers de Lutte Contre le Cancer (FNCLCC) grading system, ossified DDLPS tended to be lower grade than non‐ossified DDLPS (mean grade: 1.88 and 2.15, respectively). Ossification in DDLPS was associated significantly with shorter local recurrence‐free survival by multivariate analysis (P = 0.02347), but metaplastic‐appearing ossification tended to be associated with longer overall survival (P = 0.1400).

    Conclusions

    The bone tissue formed in DDLPS was mainly neoplastic regardless of its morphology and maturity, which highlighted the osteogenic differentiation of the tumour cells. DDLPS patients with osteogenic differentiation tended to suffer from earlier local recurrences, which did not necessarily lead to poor life outcomes.

    DOI: 10.1111/his.13421

    researchmap

  18. Rheostatic CD44 isoform expression and its association with oxidative stress in human malignant mesothelioma International journal

    Shan Hwu Chew, Yasumasa Okazaki, Shinya Akatsuka, Shenqi Wang, Li Jiang, Yuuki Ohara, Fumiya Ito, Hideyuki Saya, Yoshitaka Sekido, Shinya Toyokuni

    Free Radical Biology and Medicine   Vol. 106   page: 91 - 99   2017.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Elsevier BV  

    DOI: 10.1016/j.freeradbiomed.2017.02.011

    researchmap

  19. Urokinase-type plasminogen activator receptor promotes proliferation and invasion with reduced cisplatin sensitivity in malignant mesothelioma International journal

    Shenqi Wang, Li Jiang, Yipeng Han, Shan Hwu Chew, Yuuki Ohara, Shinya Akatsuka, Liang Weng, Koji Kawaguchi, Takayuki Fukui, Yoshitaka Sekido, Kohei Yokoi, Shinya Toyokuni

    Oncotarget   Vol. 7 ( 43 ) page: 69565 - 69578   2016.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Impact Journals, LLC  

    DOI: 10.18632/oncotarget.11829

    researchmap

  20. Dual preventive benefits of iron elimination by desferal in asbestos‐induced mesothelial carcinogenesis International journal

    Li Jiang, Shan‐Hwu Chew, Kosuke Nakamura, Yuuki Ohara, Shinya Akatsuka, Shinya Toyokuni

    Cancer Science   Vol. 107 ( 7 ) page: 908 - 915   2016.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Wiley  

    Asbestos‐induced mesothelial carcinogenesis is currently a profound social issue due to its extremely long incubation period and high mortality rate. Therefore, procedures to prevent malignant mesothelioma in people already exposed to asbestos are important. In previous experiments, we established an asbestos‐induced rat peritoneal mesothelioma model, which revealed that local iron overload is a major cause of pathogenesis and that the induced genetic alterations are similar to human counterparts. Furthermore, we showed that oral administration of deferasirox modified the histology from sarcomatoid to the more favorable epithelioid subtype. Here, we used i.p. administration of desferal to evaluate its effects on asbestos‐induced peritoneal inflammation and iron deposition, as well as oxidative stress. Nitrilotriacetate was used to promote an iron‐catalyzed Fenton reaction as a positive control. Desferal significantly decreased peritoneal fibrosis, iron deposition, and nuclear 8‐hydroxy‐2′‐deoxyguanosine levels in mesothelial cells, whereas nitrilotriacetate significantly increased all of them. Desferal was more effective in rat peritoneal mesothelial cells to counteract asbestos‐induced cytotoxicity than in murine macrophages (RAW264.7). Furthermore, rat sarcomatoid mesothelioma cells were more dependent on iron for proliferation than rat peritoneal mesothelial cells. Because inflammogenicity of a fiber is proportionally associated with subsequent mesothelial carcinogenesis, iron elimination from the mesothelial environment can confer dual merits for preventing asbestos‐induced mesothelial carcinogenesis by suppressing inflammation and mesothelial proliferation simultaneously.

    DOI: 10.1111/cas.12947

    researchmap

    Other Link: https://onlinelibrary.wiley.com/doi/full-xml/10.1111/cas.12947

▼display all

Books 2

  1. 免疫チェックポイント阻害によるがん治療 (特集 抗体医薬・生物学的製剤療法の現状と課題)

    大原 悠紀, 西川 博嘉

    科学評論社 臨床免疫・アレルギー科72(3), 276-282, 2019  2019 

     More details

  2. ロビンス基礎病理学 原書10版

    監訳 豊國伸哉, 高橋雅英( Role: Joint translator ,  第11章 心臓)

    丸善出版 エルゼビア ジャパン  2018.1 

     More details

Research Project for Joint Research, Competitive Funding, etc. 2

  1. 悪性中皮腫の発症・進展を制御する癌関連線維芽細胞の役割の解明

    2017.1 - 2017.12

    一般社団法人 名古屋大学医師会  平成28年度 研究助成 

      More details

    Authorship:Principal investigator 

  2. 悪性中皮腫の病態、予防、新規治療に関する研究

    2014.4 - 2018.3

    公益財団法人武田科学振興財団  医学部博士課程奨学助成 

 

Teaching Experience (On-campus) 3

  1. 基礎セミナー

    2024

  2. 基礎医学セミナー

    2015

  3. 基礎医学セミナー

    2014